CN104394873A - 全身麻醉药与氢组合而成的药品 - Google Patents

全身麻醉药与氢组合而成的药品 Download PDF

Info

Publication number
CN104394873A
CN104394873A CN201380028933.5A CN201380028933A CN104394873A CN 104394873 A CN104394873 A CN 104394873A CN 201380028933 A CN201380028933 A CN 201380028933A CN 104394873 A CN104394873 A CN 104394873A
Authority
CN
China
Prior art keywords
hydrogen
anesthetic
general
anesthetics
induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380028933.5A
Other languages
English (en)
Chinese (zh)
Inventor
风间富荣
佐藤泰司
与那岭龙二
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maruishi Pharmaceutical Co Ltd
Original Assignee
Maruishi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maruishi Pharmaceutical Co Ltd filed Critical Maruishi Pharmaceutical Co Ltd
Publication of CN104394873A publication Critical patent/CN104394873A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380028933.5A 2012-05-31 2013-05-30 全身麻醉药与氢组合而成的药品 Pending CN104394873A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012125535 2012-05-31
JP2012-125535 2012-05-31
PCT/JP2013/065094 WO2013180240A1 (ja) 2012-05-31 2013-05-30 全身麻酔薬と、水素とを組み合わせてなる、医薬

Publications (1)

Publication Number Publication Date
CN104394873A true CN104394873A (zh) 2015-03-04

Family

ID=49673427

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380028933.5A Pending CN104394873A (zh) 2012-05-31 2013-05-30 全身麻醉药与氢组合而成的药品

Country Status (16)

Country Link
US (1) US20150079197A1 (enExample)
EP (1) EP2857026A4 (enExample)
JP (1) JP6168420B2 (enExample)
KR (1) KR20150018832A (enExample)
CN (1) CN104394873A (enExample)
AU (1) AU2013268366A1 (enExample)
BR (1) BR112014029260A2 (enExample)
CA (1) CA2874579A1 (enExample)
HK (1) HK1205450A1 (enExample)
IL (1) IL235718A0 (enExample)
IN (1) IN2014MN02090A (enExample)
MX (1) MX2014014543A (enExample)
NZ (1) NZ701553A (enExample)
RU (1) RU2014152690A (enExample)
SG (1) SG11201407489TA (enExample)
WO (1) WO2013180240A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024078545A1 (zh) * 2022-10-11 2024-04-18 上海氢医医疗科技有限公司 氢气吸入治疗自闭症

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6253029B2 (ja) * 2015-01-21 2017-12-27 大陽日酸株式会社 麻酔器用取付キット
US20180338995A1 (en) * 2017-05-23 2018-11-29 Perricone Hydrogen Water Company, Llc Systems and methods for treatments using hydrogen and/or noble gases
US11129848B2 (en) * 2017-08-08 2021-09-28 Perricone Hydrogen Water Company, Llc Medication enhancement using hydrogen
US20210222174A1 (en) * 2018-06-29 2021-07-22 John Mansell Compositions and methods for the treatment of anesthesia-induced neurotoxicity
US11123365B2 (en) 2019-11-18 2021-09-21 Perricone Hydrogen Water Company, Llc Compositions comprising palmitoylethanolamide and hydrogen water, and methods thereof
JP7019910B2 (ja) * 2020-07-21 2022-02-16 ＭｉＺ株式会社 薬の副作用、薬の副作用に関連する症状、および／または、治療に伴う副作用を予防および／または改善するための組成物
CN119303200A (zh) * 2024-12-17 2025-01-14 山东百多安医疗器械股份有限公司 一种可以释放氢气减少神经损伤的麻醉机

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. BOSCOLO ET AL.: "The abolishment of anesthesia-induced cognitive impairment by timely protection of mitochondria in the developing rat brain: The importance of free oxygen radicals and mitochondrial integrity", 《NEUROBIOLOGY OF DISEASE》 *
HIROAKI KOBAYASHI ET AL.: "EFFECTS OF HYDROGEN GAS IN A MOUSE COLD INDUCED BRAIN INJURY MODEL", 《JOURNAL OF NEUROTRAUMA》 *
YI HUANG ETC: "Beneficial effects of hydrogen gas against spinal cord ischemia-reperfusion injury in rabbits", 《BRAIN RESEARCH》 *
陈晓等: "氢的选择性抗氧化作用研究进展", 《基础医学与临床》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024078545A1 (zh) * 2022-10-11 2024-04-18 上海氢医医疗科技有限公司 氢气吸入治疗自闭症

Also Published As

Publication number Publication date
KR20150018832A (ko) 2015-02-24
CA2874579A1 (en) 2013-12-05
WO2013180240A1 (ja) 2013-12-05
EP2857026A4 (en) 2015-11-04
US20150079197A1 (en) 2015-03-19
BR112014029260A2 (pt) 2017-06-27
JP6168420B2 (ja) 2017-07-26
SG11201407489TA (en) 2014-12-30
MX2014014543A (es) 2015-06-05
IN2014MN02090A (enExample) 2015-09-04
NZ701553A (en) 2016-06-24
RU2014152690A (ru) 2016-07-20
IL235718A0 (en) 2015-01-29
EP2857026A1 (en) 2015-04-08
AU2013268366A1 (en) 2015-03-19
JPWO2013180240A1 (ja) 2016-01-21
HK1205450A1 (en) 2015-12-18

Similar Documents

Publication Publication Date Title
CN104394873A (zh) 全身麻醉药与氢组合而成的药品
Bertolino et al. Beneficial effects of co‐ultramicronized palmitoylethanolamide/luteolin in a mouse model of autism and in a case report of autism
Lee et al. Effects of systemic administration of ibuprofen on stress response in a rat model of post-traumatic stress disorder
Karen et al. Effect of propofol in the immature rat brain on short-and long-term neurodevelopmental outcome
Resende et al. Effects of sodium butyrate in animal models of mania and depression: implications as a new mood stabilizer
Peng et al. Cistanches alleviates sevoflurane‐induced cognitive dysfunction by regulating PPAR‐γ‐dependent antioxidant and anti‐inflammatory in rats
Sun et al. Gastrodin relieved complete Freund's adjuvant-induced spontaneous pain by inhibiting inflammatory response
Shan et al. Dexmedetomidine ameliorates the neurotoxicity of sevoflurane on the immature brain through the BMP/SMAD signaling pathway
Cui et al. Reward ameliorates depressive-like behaviors via inhibition of the substantia innominata to the lateral habenula projection
Guimarães et al. Nitrous oxide as an adjunctive therapy in major depressive disorder: a randomized controlled double-blind pilot trial
Murakami et al. Long-term systemic exposure to rotenone induces central and peripheral pathology of Parkinson’s disease in mice
Hu et al. Hydrogen sulfide attenuates isoflurane-induced neuroapoptosis and cognitive impairment in the developing rat brain
Haelewyn et al. Neuroprotection by nitrous oxide: facts and evidence
Sun et al. Neuronal nitric oxide synthase in dorsal raphe nucleus mediates PTSD-like behaviors induced by single-prolonged stress through inhibiting serotonergic neurons activity
Nishigaki et al. Acute and long-term effects of haloperidol on surgery-induced neuroinflammation and cognitive deficits in aged rats
Flores et al. Neonatal olfactory bulbectomy enhances locomotor activity, exploratory behavior and binding of NMDA receptors in pre-pubertal rats
Harding et al. Prenatal exposure to valproic acid and treatment with intranasal oxytocin have sex-specific effects on behavior in Long Evans rats
Chen et al. The combined use of gamma-aminobutyric acid and walnut peptide enhances sleep in mice
Zhao et al. Repeated exposure to sevoflurane in neonatal rats impairs cognition in adulthood via the PKA-CREB-BDNF signaling pathway
Ribeiro et al. A single intraperitoneal injection of ketamine does not affect spatial working, reference memory or neurodegeneration in adult mice: an animal study
Stairs et al. Environmental enrichment increases cue-dependent freezing and behavioral despair but decreases anxiety-like behavior in rats
CA2852978C (en) Methods for the prevention and/or treatment of memory impairment
Wu et al. KIF17 mediates the learning and memory impairment in offspring induced by maternal exposure to propofol during middle pregnancy
Qi et al. Depressive‐like history alters persistent pain behavior in rats: Opposite contribution of frontal cortex and amygdala implied
Wang et al. A new trick of INPP4A: Decreased expression of INPP4A in patients with temporal lobe epilepsy and pilocarpine‐induced rat model

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150304